Last $12.20 USD
Change Today +0.03 / 0.25%
Volume 264.0
As of 10:33 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

elekta ab-b shs-unspon adr (EKTAY) Snapshot

Open
$12.20
Previous Close
$12.17
Day High
$12.20
Day Low
$12.20
52 Week High
08/14/13 - $17.74
52 Week Low
07/21/14 - $12.02
Market Cap
4.7B
Average Volume 10 Days
2.3K
EPS TTM
--
Shares Outstanding
368.6M
EX-Date
08/28/14
P/E TM
--
Dividend
$0.22
Dividend Yield
2.50%
Current Stock Chart for ELEKTA AB-B SHS-UNSPON ADR (EKTAY)

Related News

No related news articles were found.

elekta ab-b shs-unspon adr (EKTAY) Related Businessweek News

No Related Businessweek News Found

elekta ab-b shs-unspon adr (EKTAY) Details

Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; The Extend program for utilization of Leksell Gamma Knife Perfexion; Elekta Axesse, an integrated stereotactic radiation therapy system; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife surgery for the treatment of brain disorders; stereotactic neurosurgery for invasive neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Compact, a gateway to RT for oncology centers; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloaders; applicators; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; and Simulix Evolution that offers image quality and workflow-based design solutions. Further, the company provides software products and services, including MOSAIQ oncology information system, Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; and decision support products, such as METRIQ and Précis-Central. The company also offers installation and implementation, service and support, remote, upgrades and accessories, and financial solutions, as well as training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

3,775 Employees
Last Reported Date: 05/28/14
Founded in 1972

elekta ab-b shs-unspon adr (EKTAY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

elekta ab-b shs-unspon adr (EKTAY) Key Developments

The Christie NHS Foundation Trust Joins Elekta and Philips Research Consortium to Develop MRI-Guided Radiation Therapy System for Cancer Treatment

Elekta and Royal Philips announced that The Christie NHS Foundation Trust (Manchester, UK) will join a consortium whose mission is to develop the clinical value of an integrated magnetic resonance imaging (MRI) guided radiation therapy system. Such a system would, in principle, improve the practice of radiotherapy via real-time visualization of cancer targets. The Christie is the seventh member to join the research consortium that assesses the novel technology, which brings together radiation therapy and MRI in a single system. The consortium also includes the University Medical Center Utrecht (Utrecht, the Netherlands), The University of Texas MD Anderson Cancer Center (Houston, Texas), The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (Amsterdam, the Netherlands), Sunnybrook Health Sciences Centre (Toronto, Ontario), The Froedtert & Medical College of Wisconsin Cancer Center (Milwaukee, Wisconsin) and The Institute of Cancer Research, working with its clinical partner The Royal Marsden NHS Foundation Trust (London, England). The Christie joined the recent research consortium meeting at Utrecht, where the clinical indications that would benefit the most from the use of MRI-guided radiation therapy were discussed. These targets are typically going to be in anatomy that changes its position and shape either from day to day or during the treatment. The consortium anticipates that the use of MRI imaging at the time of treatment will result in a considerable increase in the accuracy of the placement of the dose, reducing the need for large safety margins around the tumor target.

Uppsala University Hospital and Elekta Signs an Research Agreement

Uppsala University Hospital and Elekta announced that they have signed an agreement to jointly work at the forefront of imaging in cancer care research. With this research agreement, Uppsala University Hospital and Elekta seek to contribute to the field of personalized care by using Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET).

Elekta AB(OM:EKTA B) dropped from OMX Nordic 40 Index

Elekta AB will be removed from the OMX Nordic 40 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKTAY:US $12.20 USD +0.03

EKTAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Accuray Inc $7.81 USD -0.06
IsoRay Inc $2.32 USD -0.13
MRI Interventions Inc $1.08 USD -0.0099
RaySearch Laboratories AB kr38.50 SEK -0.60
Varian Medical Systems Inc $81.22 USD -0.93
View Industry Companies
 

Industry Analysis

EKTAY

Industry Average

Valuation EKTAY Industry Range
Price/Earnings 27.9x
Price/Sales 2.9x
Price/Book 4.9x
Price/Cash Flow 25.7x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEKTA AB-B SHS-UNSPON ADR, please visit www.elekta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.